Last reviewed · How we verify
Efavirenz (EFV)
Efavirenz (EFV) is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) Small molecule drug developed by Janssen-Cilag S.p.A.. It is currently FDA-approved for HIV-1 infection (in combination with other antiretroviral agents). Also known as: Sustiva, EFV.
Efavirenz inhibits HIV reverse transcriptase, blocking the enzyme that converts viral RNA into DNA and preventing HIV replication.
Efavirenz inhibits HIV reverse transcriptase, blocking the enzyme that converts viral RNA into DNA and preventing HIV replication. Used for HIV-1 infection (in combination with other antiretroviral agents).
At a glance
| Generic name | Efavirenz (EFV) |
|---|---|
| Also known as | Sustiva, EFV |
| Sponsor | Janssen-Cilag S.p.A. |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV reverse transcriptase and blocks its catalytic activity. By preventing the conversion of viral RNA to DNA, it interrupts the HIV replication cycle early in infection. It is typically used as part of combination antiretroviral therapy (cART) to suppress viral load in HIV-infected patients.
Approved indications
- HIV-1 infection (in combination with other antiretroviral agents)
Common side effects
- Dizziness
- Rash
- Nausea
- Headache
- Neuropsychiatric effects (depression, anxiety, impaired concentration)
- Elevated liver enzymes
- Lipid abnormalities
Key clinical trials
- The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY (NA)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Efavirenz (EFV) Intensification (PHASE4)
- Contributing Factors for Poor HIV Treatment Response in Children With TB/HIV Coinfection
- Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (PHASE3)
- A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV (PHASE2)
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Efavirenz (EFV) CI brief — competitive landscape report
- Efavirenz (EFV) updates RSS · CI watch RSS
- Janssen-Cilag S.p.A. portfolio CI
Frequently asked questions about Efavirenz (EFV)
What is Efavirenz (EFV)?
How does Efavirenz (EFV) work?
What is Efavirenz (EFV) used for?
Who makes Efavirenz (EFV)?
Is Efavirenz (EFV) also known as anything else?
What drug class is Efavirenz (EFV) in?
What development phase is Efavirenz (EFV) in?
What are the side effects of Efavirenz (EFV)?
What does Efavirenz (EFV) target?
Related
- Drug class: All Non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs
- Target: All drugs targeting HIV reverse transcriptase
- Manufacturer: Janssen-Cilag S.p.A. — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection (in combination with other antiretroviral agents)
- Also known as: Sustiva, EFV
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing